Loading
Phio Pharmaceuticals Corp. Stock: price and insider trades · United States
3 insiders bought €51k of shares over the last 90 days, the latest by Plott Ronald Todd, filed 30 Sept 2026.
Cluster: 3 buyers in 30 daysPhio Pharmaceuticals Corp.: what insiders have been doing
Phio Pharmaceuticals Corp. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). 7 insiders have disclosed 23 filings since 20 October 2025.
Only purchases show up on the open market, 12 purchases in all worth €79k, filed by 3 insiders. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The largest single trade was a purchase of €15k by Plott Ronald Todd, published on 20 August 2026, equal to 0.14% of the market capitalisation. Among those who bought: 2 senior executives and 1 chief executive.
Compared with its exchange (5,453 companies, median 22 filings), a count of 23 filings is above the norm. Looking back to 2017, when coverage begins, insiders filed 47 purchases and 4 sales.
In the case of 6 purchases, another manager of the company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The latest purchase is recent: it was published 21 days ago, on 30 September 2026. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. US insiders must file a Form 4 within two business days of a trade.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
142
Thresholds
n/a
Buy Volume
€168,150
47 ops. · all time
Sell Volume
€90,424
4 ops. · all time
Who traded when
BuySaleRobert J. Bitterman10 buys
Ronald Todd Plott3 buys
Patricia A. Bradford2 buys
Robert L. Ferrara2 buys
Since the insiders bought
- -11.8%Entry US$1.02 · Close 16 Oct 2026 US$0.90
- -23.7%Entry US$1.18 · Close 16 Oct 2026 US$0.90
- -25.6%Entry US$1.21 · Close 16 Oct 2026 US$0.90
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.87
Analyst consensus
1 analysts1.00/5
US$14.00Target US$14.00(+1507%)US$14.00
Income statement
EBITDA-US$9.2M
Net income-US$8.7M0.0% margin
Valuation
PER (forward)-1.4x
P/Book0.8x
Beta0.84
Balance sheet & cash
Market capUS$10.1M
Free Cash Flow-US$8M
Profitability & ownership
ROE-113.7%
ROA-65.8%
% insiders8.0%
% institutions10.2%
Last declaration on 30 September 2026
Declarations142 total
5,000 shares@ US$1.030.042% mcap19.0% of flowCommon Stock, $.0001 par valueSEC:0001683168-26-007499:0
Canonical exit: 27 Dec 2026 (T+90)
5,000 shares@ US$1.040.043% mcap19.2% of flowCommon Stock, $.0001 par valueSEC:0001683168-26-007499:1
Canonical exit: 28 Dec 2026 (T+90)
400,000 shares0Common Stock, $.0001 par valueSEC:0001683168-26-007483:0
17,000 shares0Common Stock, $.0001 par valueSEC:0001683168-26-007482:0
108,000 shares0Common Stock, $.0001 par valueSEC:0001683168-26-007481:0
6,500 shares@ US$1.01270.064% mcap35.1% of flowCommon Stock, $.0001 par valueSEC:0001683168-26-007432:0
Canonical exit: 23 Dec 2026 (T+90)
2,000 shares@ US$1.02890.020% mcap1.4% of flowCommon Stock, $.0001 par valueSEC:0001683168-26-007321:0
Canonical exit: 21 Dec 2026 (T+90)
12,000 shares@ US$1.030.10% mcap64.9% of flowCommon Stock, $.0001 par valueSEC:0001683168-26-007192:0
Canonical exit: 14 Dec 2026 (T+90)
68,550 shares@ US$1.030.58% mcap48.5% of flowCommon Stock, $.0001 par valueSEC:0001683168-26-007159:0
12,888 shares@ US$1.030.11% mcap100.0% of flowCommon Stock, $.0001 par valueSEC:0001683168-26-007158:0
15,000 shares@ US$1.140.14% mcap100.0% of flowCommon Stock, $.0001 par valueSEC:0001683168-26-006620:0
Canonical exit: 17 Nov 2026 (T+90)
10,000 shares@ US$1.060.088% mcap7.3% of flowCommon Stock, $.0001 par valueSEC:0001683168-26-006592:0
Canonical exit: 16 Nov 2026 (T+90)
10,000 shares@ US$0.996.5% of flowCommon Stock, $.0001 par valueSEC:0001683168-26-005164:0
Canonical exit: 24 Sept 2026 (T+90)
23,800 shares0Common Stock, $.0001 par valueSEC:0001683168-26-000809:0
47,000 shares0Common Stock, $.0001 par valueSEC:0001683168-26-000807:0
18,500 shares0Common Stock, $.0001 par valueSEC:0001683168-26-000805:0
16,600 shares0Common Stock, $.0001 par valueSEC:0001683168-26-000813:0
16,600 shares0Common Stock, $.0001 par valueSEC:0001683168-26-000811:0
120,000 shares0Common Stock, $.0001 par valueSEC:0001683168-26-000803:0
5,000 shares@ US$1.033.5% of flowCommon Stock, $.0001 par valueSEC:0001683168-26-000013:0
Canonical exit: 31 Mar 2026 (T+90)
5,000 shares@ US$1.023.5% of flowCommon Stock, $.0001 par valueSEC:0001683168-25-009349:0
Canonical exit: 23 Mar 2026 (T+90)
5,000 shares@ US$1.143.9% of flowCommon Stock, $.0001 par valueSEC:0001683168-25-008639:0
Canonical exit: 19 Feb 2026 (T+90)
5,000 shares@ US$1.274.4% of flowCommon Stock, $.0001 par valueSEC:0001683168-25-008537:0
Canonical exit: 16 Feb 2026 (T+90)
23,100 shares0Common Stock, $.0001 par valueSEC:0001683168-25-006986:0
16,200 shares0Common Stock, $.0001 par valueSEC:0001683168-25-006959:0
25 of 142 declarations
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. is a U.S.-listed biotechnology company trading on the NASDAQ market in the United States. It is focused on immuno-oncology drug discovery and development, built around its proprietary INTASYL™ platform, a self-delivering RNA interference technology designed to modulate disease-relevant gene expression without relying on conventional delivery systems. From an investor’s perspective, Phio remains a development-stage micro-cap biotech: it has no approved commercial product, limited operating history, and a valuation that is highly sensitive to clinical progress, intellectual property protection, and access to capital.
The company’s history traces back to Cutanea Life Sciences, which was founded by CEO Robert Bitterman; Phio later adopted its current name to reflect a strategic pivot toward cancer immunotherapy. According to its SEC filings, the company relocated its corporate headquarters from Marlborough, Massachusetts to King of Prussia, Pennsylvania, while maintaining a small laboratory presence in Worcester, Massachusetts. That move, together with broader cost rationalization efforts, underscores a lean operating model typical of early-stage biopharma companies.
Read moreShow less
Phio’s core business is concentrated on advancing product candidates derived from INTASYL. The company identifies PH-762 as its lead development compound and also references PH-894 as part of its pipeline. In preclinical work, INTASYL has been evaluated against multiple immune-oncology targets, including PD-1, BRD4, CTLA-4, TIGIT and CTGF. The company also emphasizes a sizeable patent estate for a company of its scale, with issued patents and patent families covering the INTASYL platform and related therapeutic uses. However, Phio is still reliant on third-party manufacturers for drug substance and clinical supply production.
In competitive terms, Phio operates in a crowded and rapidly evolving immuno-oncology field dominated by much larger pharmaceutical groups, venture-backed biotech peers, academic research institutions and other public and private developers. Its potential differentiation lies in the ease of incorporating INTASYL into existing cell-therapy workflows and in the platform’s self-delivering design. At the same time, the company faces the classic risks of an early clinical biotech: uncertain efficacy, safety and manufacturability, as well as a strong likelihood of future financing needs.
A key recent development was disclosed in Phio’s Form 10-Q for the quarter ended September 30, 2025. In July 2025, the company entered into a comprehensive drug substance development services agreement with a U.S. manufacturing partner to support analytical, process-development and cGMP manufacturing work for PH-762. This followed the termination of its clinical co-development arrangement with AgonOx and the wind-down of the associated Phase 1 study. For investors in France, Belgium or Switzerland, Phio is best viewed as a high-risk NASDAQ-listed healthcare story driven by platform validation, pipeline execution and financing discipline rather than near-term revenues.
